Literature DB >> 18177500

Expression of infectious murine leukemia viruses by RAW264.7 cells, a potential complication for studies with a widely used mouse macrophage cell line.

Janet W Hartley1, Leonard H Evans, Kim Y Green, Zohreh Naghashfar, Alfonso R Macias, Patricia M Zerfas, Jerrold M Ward.   

Abstract

The mouse macrophage-like cell line RAW264.7, the most commonly used mouse macrophage cell line in medical research, was originally reported to be free of replication-competent murine leukemia virus (MuLV) despite its origin in a tumor induced by Abelson MuLV containing Moloney MuLV as helper virus. As currently available, however, we find that it produces significant levels of ecotropic MuLV with the biologic features of the Moloney isolate and also MuLV of the polytropic or MCF class. Newborn mice developed lymphoma following inoculation with the MuLV mixture expressed by these cells. These findings should be considered in interpretation of increasingly widespread use of these cells for propagation of other viruses, studies of biological responses to virus infection and use in RNA interference and cell signalling studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18177500      PMCID: PMC2253558          DOI: 10.1186/1742-4690-5-1

Source DB:  PubMed          Journal:  Retrovirology        ISSN: 1742-4690            Impact factor:   4.602


Background

In contrast to most other mouse-derived cell cultures, the macrophage-like cell line RAW264.7 [1] supports replication of murine noroviruses and is widely used for this purpose [2]. Further, in studies of a mouse model of severe respiratory disease, RAW264.7 was found to be uniquely efficient for propagation of the causative agent, pneumonia virus of mice, and for measuring infection-related proinflammatory mediators [3]. In addition, because of ease of cell propagation, high efficiency for DNA transfection, sensitivity to RNA interference [4], possession of receptors for many relevant ligands, and other properties, RAW264.7 has been chosen by the Alliance for Cellular Signaling as the primary experimental system for their large-scale study of signaling pathways [5]. The RAW264.7 cell line was derived about 30 years ago from a tumor developing in a BAB/14 mouse, a BALB/c IgH congenic strain, inoculated with Abelson murine leukemia virus (MuLV), a defective transforming virus containing the v-abl tyrosine kinase oncogene, and replication-competent Moloney (Mo-MuLV) that served as helper virus [1]. At the time it was described, tests for presence of replication competent virus were negative and cells in the American Type Culture Collection repository (ATCC TIB-71) were so designated until recently. As far as we can determine, ATCC is the major if not sole, commercial source of this cell line. To date, a Pubmed retrieval lists over 1500 publications that have used the RAW264.7 cell line in the research reported.

Results and conclusion

In the course of evaluating RAW264.7 cells for use in isolation and propagation of new isolates of murine norovirus, electron microscopy revealed particles with C-type morphology (data not shown). To look for expression of MuLV-encoded protein, RAW264.7 cell pellets were fixed in formalin and embedded in paraffin; after antigen retrieval using proteinase K, sections were stained by avidin-biotin immunohistochemistry (IHC) using group-reactive goat anti-Rauscher MuLV p30 antibody (from the Division of Cancer Cause and Prevention, NCI, Frederick, MD and obtained from Dr. Sandra Ruscetti). Abundant expression of MuLV p30 was revealed (Figure 1). Cell surface expression of MuLV gp70 protein (SU) was revealed by immunofluorescence assay using the broadly reactive monoclonal antibody 83A25 [6] (data not shown).
Figure 1

MuLV p30 expressed by RAW264.7 cells in a formalin-fixed, paraffin-embedded cell pellet. (Avidin biotin IHC, ×1000).

MuLV p30 expressed by RAW264.7 cells in a formalin-fixed, paraffin-embedded cell pellet. (Avidin biotin IHC, ×1000). In tests for the presence of infectious MuLV, cell-free harvests of RAW264.7 supernatants from two separate acquisitions from ATCC were positive using the XC plaque assay [7] in SC-1 cells [8], indicating the presence of virus of the ecotropic MuLV class. Titers of several independent harvests ranged from 101.2 to 104.2 XC plaque-forming units (pfu) per ml. Lower titers were associated with high density cell growth and consequent low pH (data not shown). Infection of cell cultures of various mouse strains by most ecotropic MuLVs is regulated by the Fv1 genotype of the mouse and the tropism of the virus. Thus, Fv1cells are permissive for N-tropic and partially restrictive for B-tropic MuLVs; the reciprocal pattern is observed for cells of Fv1mice. A few isolates with long laboratory passage histories, including Mo-MuLV, are not restricted by either allele and are termed NB-tropic. XC plaque titration of RAW264.7 supernatant in NIH3T3 (Fv1) and BALB3T3 (Fv1) cells gave essentially identical titers (104.1 and 104.2, respectively) indicating NB-tropism. Additionally, focal immunofluoresence assays (IFA) [9] utilizing monoclonal hybridoma antibody mAb538, specifically reactive with the Mo-MuLV envelope (SU) protein [10], were positive in NIH3T3 cells and to about 1000-fold lower titer in Mus dunni cells, confirming the presence of a virus with ecotropic Mo-MuLV biological properties. Why earlier tests failed to detect ecotropic MuLV in RAW264.7 cells is unknown but possible explanations include differences in culture conditions and the health of the cells when assayed or in sensitivity of the tests used in different laboratories at different times. It is well established that mouse-passaged ecotropic MuLV stocks, like the Mo-MuLV helper virus used in establishing RAW264.7 [1], frequently contain MuLV of other classes – xenotropic and recombinant MuLVs that result from interaction between ecotropic sequences and polytropic, also referred to as MCF, proviral sequences. Indeed, isolates of these classes were reported in a stock of Abelson MuLV complex [11]. Comparative IFA titrations of a RAW264.7 supernatant were performed in NIH3T3 cells using anti-Mo-MuLV mAb538 and two mAbs that specifically detect polytropic MuLV SU antigen: 514, reactive with all tested polytropic MuLVs [11], and HY7, reactive with certain polytropic subsets [12,13]. Titer estimates of 104 and 104.5 ffu per ml were obtained for polytropic and Moloney ecotropic MuLVs, respectively. Negative results with mAbs reactive with xenotropic MuLVs indicated no significant population of this class in RAW264.7 supernatants (data not shown). Thus, RAW264.7 cells express approximately equal levels of ecotropic Moloney-like and polytropic MCF MuLVs, with some variation in titer probably depending on culture conditions. Inoculation of neonatal mice of sensitive strains with Mo-MuLV results in development of almost exclusively T cell lymphoblastic lymphomas (LL), mostly of thymic origin. To determine the pathogenic potential of harvests from RAW264.7 cells, we inoculated 1–2 day old Cr:NIH(S) (NIH Swiss) and BALB/cAnNCr (BALB/c) mice, 0.02 ml intraperitoneally and in the region of the thymus with a filtered supernatant of RAW264.7 cells or 264.7 SC-1, a harvest of SC-1 cells infected with RAW264.7 supernatant and passaged twice. For comparison, mice were similarly inoculated with Mo-MuLV (molecularly cloned and propagated in SC-1 cells). Controls were uninoculated mice of the same strains. Mice were obtained from the Division of Cancer Treatment, NCI, Frederick, MD and studied under NIAID Animal Care and Use Committee approved protocols and housing. Mice were observed for 8 to 12 months and necropsied when signs of splenomegaly, lymphadenopathy, labored breathing or lethargy were noted or the experiment was terminated at 12 months. Diagnosis was based on gross findings, microscopic examination of H&E stained formalin fixed, paraffin embedded tissues or studied by IHC using the anti-p30 antibody, anti-CD3 for T-cell lineage identification (DAKO Corporation, Carpinteria, CA Catalog # A452), and anti-PAX5 for B-cell lineage (Goat anti-Pax 5, Santa Cruz Biotechnology, Santa Cruz, CA, Catalog #sc-1974) [14]. Criteria for histopathological diagnosis were as described [15]. As shown in Table 1, there were no significant differences in tumor incidence between NIH Swiss and BALB/c recipients but virus dose was clearly an important variable for those inoculated with the viruses produced by RAW264.7 cells (264.7MuLVmix), with higher concentrations tending to give shorter latencies and more diversity in pathology. Mo-MuLV induced mostly T-cell LL, characterized histologically by diffuse growth of CD3+ T-cell lymphoblasts usually originating in the thymus and metastasizing to the spleen, liver and other organs. Most mice presented with significantly enlarged thymus (16/19), spleen weights of over 600 mg (18/19) and variable lymphadenopathy. Mice injected with 264.7-MuLVmix expressed MuLV p30 in spleen (Figure 2), megakaryocytes, and many tissues prior to tumor development and in all lymphomas examined (e.g., Figure 3). Splenomegaly and lymphadenopathy were variable with spleen weights ranging from 100 to 1800 mg. The majority of hematopoietic neoplasms were classified as LL (26/34). Of these, 19 were of T-cell origin, CD3+ and PAX5-; 13 were associated with enlarged thymus (Figure 4). In contrast to CD3+ Mo-MuLV-induced LL (Figure 5), the remaining seven LL were of B-cell origin, based on PAX5+ IHC (Figure 6) and CD3 negativity. Spleen weights ranged from 450 to 770 mg and lymph node size was variable. In addition, one BALB/c mouse had an early splenic marginal zone B cell lymphoma (MZL) as well as early thymic T-LL. To our knowledge, spontaneous splenic MZL has not been reported in this strain. There are sporadic reports of exogenous virus induction of B cell lymphomas in mice by a variety of ecotropic and polytropic MuLVs [16,17], none to our knowledge involving Mo-MuLV except for pre-B LL induction in Eμ-myc transgenic mice [18]. Pre-B, immature B cells and plasma cells are the target cells of Abelson MuLV [19] and mice infected with the LP-BM5 complex, which includes a defective immunodeficiency-inducing virus, develop transplantable clonal B-cell populations [20]. We did not detect Abelson transforming capacity in tissue culture assays (data not shown), but it is conceivable that B-cell LLs found in our study might be causally related to the Abelson genome present in RAW264.7 cells. Alternatively, B cell pathology may be associated with the polytropic virus population present in RAW264.7 supernatants, likely in synergy with Mo-MuLV. Further testing with cloned virus preparations would be necessary to resolve these possibilities.
Table 1

Comparative Pathogenicity of 264.7MuLVs and Mo-MuLV in Mice

Diagnosis3
Mouse StrainInoculumVirus dose1#pos/#inoc2Latency (days)% positiveLL-TLL-BErythroidOther
NIH SwissMo-MuLV104.46/687 +/- 1610040240
102.210/1093 +/- 1310010000
RAW264.7 cell-free supernatant101.05/7259 +/- 687130115
102.512/15163 +/- 68805430
264.7-MuLV, SC-1 passage102.23/3146 +/- 241002100
None-0/5
BALB/cMo-MuLV104.45/598 +/- 141005000
RAW264.7 cell-free supernatant101.02/22551001010
102.57/12168 +/- 535842410
264.7-MuLV SC-1 passage102.25/5216 +/- 8410040016
None-0/4

1 pfu/mouse of ecotropic MuLV, based on XC plaque titration in SC-1 cells; polytropic MuLV titer not determined.

2 number of mice positive for hematopoietic disease/number inoculated.

3 LL, lymphoblastic lymphoma;, T, T-cell lineage; B, B-cell lineage; erythroid, erythroleukemia (PAX5 and CD3 negative).

4 One case also had early Thymic T-LL.

5 Mast cell tumor, spleen and bone marrow (366d post-inoculation).

6 Early splenic marginal zone lymphoma (295d post-inoculation) ; also very early T-LL in thymus.

Figure 2

MuLV p30 expression in spleen 8 weeks post injection of 264.7-MuLV, SC-1 prior to lymphoma development (IHC, hematoxylin, ×100).

Figure 3

MuLV p30 in splenic follicular B-cells and megakaryocytes in a mouse injected with 264.7-MuLV and that developed thymic lymphoma at 119 days (IHC, hematoxylin, ×200).

Figure 4

Thymic lymphoma induced by 264.7-MuLV, 164 days post injection. Note large spleen.

Figure 5

Thymic lymphoma in 264.7-MuLV infected mouse showing CD3+ lymphoma cells in lung metastases (IHC, hematoxylin, ×200).

Figure 6

PAX5 expression in bone marrow metastases of a B-cell lymphoma induced by RAW 264.7-MuLV (IHC, hematoxylin, ×100).

MuLV p30 expression in spleen 8 weeks post injection of 264.7-MuLV, SC-1 prior to lymphoma development (IHC, hematoxylin, ×100). MuLV p30 in splenic follicular B-cells and megakaryocytes in a mouse injected with 264.7-MuLV and that developed thymic lymphoma at 119 days (IHC, hematoxylin, ×200). Thymic lymphoma induced by 264.7-MuLV, 164 days post injection. Note large spleen. Thymic lymphoma in 264.7-MuLV infected mouse showing CD3+ lymphoma cells in lung metastases (IHC, hematoxylin, ×200). PAX5 expression in bone marrow metastases of a B-cell lymphoma induced by RAW 264.7-MuLV (IHC, hematoxylin, ×100). Comparative Pathogenicity of 264.7MuLVs and Mo-MuLV in Mice 1 pfu/mouse of ecotropic MuLV, based on XC plaque titration in SC-1 cells; polytropic MuLV titer not determined. 2 number of mice positive for hematopoietic disease/number inoculated. 3 LL, lymphoblastic lymphoma;, T, T-cell lineage; B, B-cell lineage; erythroid, erythroleukemia (PAX5 and CD3 negative). 4 One case also had early Thymic T-LL. 5 Mast cell tumor, spleen and bone marrow (366d post-inoculation). 6 Early splenic marginal zone lymphoma (295d post-inoculation) ; also very early T-LL in thymus. Six of 34 264.7MuLVmix- and 2 of 16 MoMuLV-induced tumors were non-lymphoid and diagnosed as erythroleukemia based on splenomegaly with a high frequency of erythroid cells and lack of reactivity with CD3 and PAX5. These neoplasms, not usually seen following Mo-MuLV infection, may be related to the generalized hyperplasia of hematopoietic lineages, including erythroid, reported in pre-leukemic Mo-MuLV-infected mice [21]. A further unusual finding was a mast cell tumor, a rarely seen mouse neoplasm that cannot unequivocally be considered related to the virus inoculation. As shown in this report, RAW264.7 cells as currently available from ATCC express ecotropic and polytropic MuLVs. The ecotropic virus has biological properties of the Mo-MuLV helper virus of the Abelson virus complex that induced the tumor from which the cell line derived. Cell-free culture supernatants containing the mixed virus population induced hematopoietic disease in newborn mice, primarily LL that were mostly of T cell type, as is characteristic of Mo-MuLV lymphomagenesis, but also some of B cell origin. This tumor-inducing potential may confound pathogenicity testing of unrelated viruses propagated in RAW264.7, especially in newborn mice. Adult mice are susceptible to infection by Mo- and other MuLVs, however [22,23], and mixed infection of MuLVs with related and unrelated viruses may have effects not directly attributable to lymphomagenicity. For example, radiation-induced RadLV enhances expression of MHC Class I genes [24] as does Mo-MuLV in cell culture [25]. Synergism between different retroviruses of low pathogenicity induces a rapidly fatal neurological disease [26], ecotropic MuLV potentiates LDV-related paralytic disease [27] and Mo-MuLV potentiates polyomavirus-induced runting syndrome [28]. Ecotropic MuLV infection of adult mice has been shown to increase B-cell proliferation, serum immunoglobulin M levels and expression of transcripts associated with B cell activation [23]. Further, infection of bone marrow cells with MoMuLV or bone marrow and primary B cells by Abelson MuLV induces expression of activation-induced cytidine deaminase (AID) by activating NFκB [29,30]. Ectopic expression of AID can result in generalized somatic hypermutation [31]. Such illustrations of unanticipated consequences of MuLV infection as well as conceivable disruptive effects of MuLV replication, including integration into cellular DNA and cell surface expression of MuLV antigens, suggest caution in experimental design and data interpretation in studies utilizing RAW264.7 cells.

Abbreviations

MuLV: Murine leukemia virus; Mo-MuLV: Moloney MuLV; IFA: Immunofluorescence focus assay; LL: Lymphoblastic lymphoma; IHC: Immunohistochemistry.

Competing interests

The author(s) declare that they have no competing interests.

Authors' contributions

JMW, KYG and JWH conceived and designed the study. JMW performed histopathological observations and carried out IHC studies. LHE carried out focal IFA. ZN performed cell culture and viral quantitation studies. PZ performed electron microscopy and first found the virus particles. AM, JWH and JMW carried out mouse studies. JWH and JMW drafted the paper.
  30 in total

1.  A single lentiviral vector platform for microRNA-based conditional RNA interference and coordinated transgene expression.

Authors:  Kum-Joo Shin; Estelle A Wall; Joelle R Zavzavadjian; Leah A Santat; Jamie Liu; Jong-Ik Hwang; Robert Rebres; Tamara Roach; William Seaman; Melvin I Simon; Iain D C Fraser
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

2.  Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging.

Authors:  M van Lohuizen; S Verbeek; B Scheijen; E Wientjens; H van der Gulden; A Berns
Journal:  Cell       Date:  1991-05-31       Impact factor: 41.582

3.  In vivo interactions of ecotropic and polytropic murine leukemia viruses in mixed retrovirus infections.

Authors:  Leonard H Evans; Marc Lavignon; Karin Peterson; Kim Hasenkrug; Shelly Robertson; Frank Malik; Kimmo Virtaneva
Journal:  J Virol       Date:  2006-05       Impact factor: 5.103

4.  A role for activation-induced cytidine deaminase in the host response against a transforming retrovirus.

Authors:  Polyxeni Gourzi; Tatyana Leonova; F Nina Papavasiliou
Journal:  Immunity       Date:  2006-06       Impact factor: 31.745

5.  B-Cell lymphoma induction by akv murine leukemia viruses harboring one or both copies of the tandem repeat in the U3 enhancer.

Authors:  J Lovmand; A B Sorensen; J Schmidt; M Ostergaard; A Luz; F S Pedersen
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

6.  A multistep process of leukemogenesis in Moloney murine leukemia virus-infected mice that is modulated by retroviral pseudotyping and interference.

Authors:  M Lavignon; L Evans
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  A model for mixed virus disease: co-infection with Moloney murine leukemia virus potentiates runting induced by polyomavirus (A2 strain) in Balb/c and NIH Swiss mice.

Authors:  I A Atencio; B Belli; M Hobbs; S F Cheng; L P Villarreal; H Fan
Journal:  Virology       Date:  1995-10-01       Impact factor: 3.616

8.  Effects of exogenous, nonleukemogenic, ecotropic murine leukemia virus infections on the immune systems of adult C57BL/6 mice.

Authors:  J S Lee; N A Giese; K L Elkins; R A Yetter; K L Holmes; J W Hartley; H C Morse
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

9.  Clonal outgrowths of T and B cells in SCID mice reconstituted with cells from mice with MAIDS.

Authors:  Y Tang; S K Chattopadhyay; J W Hartley; T N Fredrickson; H C Morse
Journal:  In Vivo       Date:  1994 Nov-Dec       Impact factor: 2.155

10.  Replication of Norovirus in cell culture reveals a tropism for dendritic cells and macrophages.

Authors:  Christiane E Wobus; Stephanie M Karst; Larissa B Thackray; Kyeong-Ok Chang; Stanislav V Sosnovtsev; Gaël Belliot; Anne Krug; Jason M Mackenzie; Kim Y Green; Herbert W Virgin
Journal:  PLoS Biol       Date:  2004-11-30       Impact factor: 8.029

View more
  37 in total

1.  Lack of effect of murine norovirus infection on a mouse model of bacteria-induced colon cancer.

Authors:  Karen C Lencioni; Rolf Drivdahl; Audrey Seamons; Piper M Treuting; Thea Brabb; Lillian Maggio-Price
Journal:  Comp Med       Date:  2011-06       Impact factor: 0.982

2.  Proteomic characterization of the cellular response to nitrosative stress mediated by s-nitrosoglutathione reductase inhibition.

Authors:  Matthew W Foster; Zhonghui Yang; David M Gooden; J Will Thompson; Carol H Ball; Meredith E Turner; Yongyong Hou; Jingbo Pi; M Arthur Moseley; Loretta G Que
Journal:  J Proteome Res       Date:  2012-03-19       Impact factor: 4.466

3.  Specificity of eicosanoid production depends on the TLR-4-stimulated macrophage phenotype.

Authors:  Paul C Norris; Donna Reichart; Darren S Dumlao; Christopher K Glass; Edward A Dennis
Journal:  J Leukoc Biol       Date:  2011-06-07       Impact factor: 4.962

4.  Analysis of two monoclonal antibodies reactive with envelope proteins of murine retroviruses: one pan specific antibody and one specific for Moloney leukemia virus.

Authors:  Leonard H Evans; Stefano Boi; Frank Malik; Kathy Wehrly; Karin E Peterson; Bruce Chesebro
Journal:  J Virol Methods       Date:  2014-02-17       Impact factor: 2.014

5.  Immunophenotype of Spontaneous Hematolymphoid Tumors Occurring in Young and Aging Female CD-1 Mice. [Corrected].

Authors:  Jerold E Rehg; Richard Rahija; Dorothy Bush; Alys Bradley; Jerrold M Ward
Journal:  Toxicol Pathol       Date:  2015-07-28       Impact factor: 1.902

6.  Innate immune responses of primary murine macrophage-lineage cells and RAW 264.7 cells to ligands of Toll-like receptors 2, 3, and 4.

Authors:  Londa J Berghaus; James N Moore; David J Hurley; Michel L Vandenplas; Barbara P Fortes; Margreet A Wolfert; Geert-Jan Boons
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2009-09-03       Impact factor: 2.268

7.  Prevention of contamination by xenotropic murine leukemia virus-related virus: susceptibility to alcohol-based disinfectants and environmental stability.

Authors:  David Palesch; Mohammad Khalid; Christina M Stürzel; Jan Münch
Journal:  Appl Environ Microbiol       Date:  2014-02-14       Impact factor: 4.792

8.  Morphologic and Immunohistochemical Characterization of Spontaneous Lymphoma/Leukemia in NSG Mice.

Authors:  Heather Tillman; Laura J Janke; Amy Funk; Peter Vogel; Jerold E Rehg
Journal:  Vet Pathol       Date:  2019-11-18       Impact factor: 2.221

9.  Unintended spread of a biosafety level 2 recombinant retrovirus.

Authors:  Alexander Stang; Elisabeth Petrasch-Parwez; Sabine Brandt; Rolf Dermietzel; Helmut E Meyer; Kai Stühler; Sven-T Liffers; Klaus Uberla; Thomas Grunwald
Journal:  Retrovirology       Date:  2009-09-22       Impact factor: 4.602

10.  A novel 3-D mineralized tumor model to study breast cancer bone metastasis.

Authors:  Siddharth P Pathi; Christine Kowalczewski; Ramya Tadipatri; Claudia Fischbach
Journal:  PLoS One       Date:  2010-01-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.